Key Points
-
The protein tyrosine phosphatase (Ptp) family comprises 107 members that are classified into four classes on the basis of the amino acid sequences of their catalytic domains.
-
Recent evidence has shown that members of the Ptp family are key components of tumorigenesis in various human cancers, exerting either putative oncogenic or tumour suppressive functions, depending on the cellular context.
-
Genetic alterations such as mutation, deletion and amplification are the most important features for putative oncogenic PTPs, whereas in most cases epigenetic modifications such as DNA methylation counter the tumour suppressive functions of PTPs.
-
Recent advances have begun to decipher the molecular mechanisms by which putative oncogenic PTPs may drive tumorigenesis in human cells. Proliferation, survival, apoptosis, vesicular trafficking, adhesion, migration and invasion are all altered by the aberrant functions of PTPs during tumour development.
-
Evidence for an association between PTPs and an increased risk of developing cancer remains controversial and elusive. Here, we focus on the pertinent genetic and functional data that support the relevance of members of the Ptp family to human cancer.
-
PTP inhibitors are currently being developed. However, a better understanding of the basic biology of PTPs in human tumour development will be required to improve the therapeutic use of such inhibitors.
Abstract
Members of the protein tyrosine phosphatase (Ptp) family dephosphorylate target proteins and counter the activities of protein tyrosine kinases that are involved in cellular phosphorylation and signalling. As such, certain PTPs might be tumour suppressors. Indeed, PTPs play an important part in the inhibition or control of growth, but accumulating evidence indicates that some PTPs may exert oncogenic functions. Recent large-scale genetic analyses of various human tumours have highlighted the relevance of PTPs either as putative tumour suppressors or as candidate oncoproteins. Progress in understanding the regulation and function of PTPs has provided insights into which PTPs might be potential therapeutic targets in human cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hunter, T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21, 140â146 (2009).
Tonks, N. K., Diltz, C. D. & Fischer, E. H. Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem. 263, 6722â6730 (1988). A landmark study reporting the characterization of the first PTP in humans.
Andersen, J. N. et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 18, 8â30 (2004).
Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148â1159 (2008). An up-to-date review that deciphers the mechanisms and clinical outcomes of gene silencing in cancer.
van Doorn, R. et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J. Clin. Oncol. 23, 3886â3896 (2005).
Wang, J. F. & Dai, D. Q. Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J. Gastroenterol. 13, 5692â5698 (2007).
Veeriah, S. et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc. Natl Acad. Sci. USA 106, 9435â9440 (2009).
Motiwala, T. et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin. Cancer Res. 13, 3174â3181 (2007).
Motiwala, T. et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc. Natl Acad. Sci. USA 101, 13844â13849 (2004).
Yeh, S. H. et al. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res. 12, 1097â1108 (2006).
Jacob, S. T. & Motiwala, T. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther. 12, 665â672 (2005).
Oka, T. et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62, 6390â6394 (2002).
Koyama, M. et al. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab. Invest. 83, 1849â1858 (2003).
Reddy, J. et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24, 732â736 (2005).
Zapata, P. D. et al. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J. Clin. Endocrinol. Metab. 87, 915â926 (2002).
Rauhala, H. E. et al. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int. J. Cancer 117, 738â745 (2005).
Xu, S., Furukawa, T., Kanai, N., Sunamura, M. & Horii, A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 50, 159â167 (2005).
Wang, Z. et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304, 1164â1166 (2004). This study used high-throughput sequence-based mutational analysis to identify somatic inactivating mutations in genes encoding PTPs and found that six function as tumour suppressors in normal colon cells.
Zhao, Y. et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor, T. Proc. Natl Acad. Sci. USA 107, 2592â2597 (2010).
Korff, S. et al. Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer 8, 329 (2008).
Solomon, D. A. et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 68, 10300â10306 (2008).
Uetani, N. et al. Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice. EMBO J. 19, 2775â2785 (2000).
Hendriks, W. J., Elson, A., Harroch, S. & Stoker, A. W. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J. 275, 816â830 (2008).
Kleppe, M. et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nature Genet. 42, 530â535 (2010).
Saha, S. et al. A phosphatase associated with metastasis of colorectal cancer. Science 294, 1343â1346 (2001). This work showed for the first time that PRL3 is involved in human cancer. More specifically, PRL3 was only consistently overexpressed in colon cancer metastasis, suggesting that PRL3 could be a new therapeutic target for these lesions.
Bardelli, A. et al. PRL-3 expression in metastatic cancers. Clin. Cancer Res. 9, 5607â5615 (2003).
Ahmadiyeh, N. et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl Acad. Sci. USA 107, 9742â9746 (2010).
Yang, S. H. et al. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. Clin. Cancer Res. 11, 612â620 (2005).
Mahlamaki, E. H. et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35, 353â358 (2002).
Zanke, B. et al. A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia 8, 236â244 (1994).
Yu, W. et al. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26, 1178â1187 (2007).
Ruivenkamp, C. A. et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nature Genet. 31, 295â300 (2002). This study provides strong evidence for the putative tumour suppressive function of DEP1 (also known as PTPRJ) in human and mouse samples.
Iuliano, R. et al. The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 23, 8432â8438 (2004).
Mita, Y. et al. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J. Cancer Res. Clin. Oncol. 136, 249â259 (2009).
Ying, J. et al. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia 20, 1173â1175 (2006).
Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999â1005 (2010).
Sacco, F. et al. Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases. J. Biol. Chem. 284, 22048â22058 (2009).
Trapasso, F. et al. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol. 25, 376â382 (2006).
Streit, S. et al. PTP-PEST phosphatase variations in human cancer. Cancer Genet. Cytogenet. 170, 48â53 (2006).
Larsen, M., Tremblay, M. L. & Yamada, K. M. Phosphatases in cell-matrix adhesion and migration. Nature Rev. Mol. Cell Biol. 4, 700â711 (2003).
Mustelin, T., Vang, T. & Bottini, N. Protein tyrosine phosphatases and the immune response. Nature Rev. Immunol. 5, 43â57 (2005).
Ostman, A., Hellberg, C. & Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nature Rev. Cancer 6, 307â320 (2006).
Tarcic, G. et al. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr. Biol. 19, 1788â1798 (2009).
Polo, S. & Di Fiore, P. P. Endocytosis conducts the cell signaling orchestra. Cell 124, 897â900 (2006).
Kovalenko, M. et al. Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 275, 16219â16226 (2000).
Grazia Lampugnani, M. et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793â804 (2003).
Zhang, X. et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase, T. Proc. Natl Acad. Sci. USA 104, 4060â4064 (2007).
Seo, Y. et al. Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. Biochem. Biophys. Res. Commun. 231, 705â711 (1997).
Matozaki, T. et al. Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers. J. Biol. Chem. 269, 2075â2081 (1994).
Sadakata, H. et al. SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis. Genes Cells 14, 295â308 (2009).
Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130â1134 (1998).
Cheng, A., Bal, G. S., Kennedy, B. P. & Tremblay, M. L. Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphatase-1B. J. Biol. Chem. 276, 25848â55 (2001).
Bjorge, J. D., Pang, A. & Fujita, D. J. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem. 275, 41439â46 (2000).
Julien, S. G. et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genet. 39, 338â46 (2007). Using genetic and pharmacological approaches, PTPN1 was identified for the first time as an oncogene and a therapeutic target in breast cancer.
Bentires-Alj, M. & Neel, B. G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67, 2420â4 (2007).
Dube, N. et al. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res. 65, 10088â95 (2005).
Novellino, L. et al. PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. Cell Signal 20, 872â883 (2008).
Anders, L. et al. Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity. Mol. Cell Biol. 26, 3917â3934 (2006).
Abaan, O. D. & Toretsky, J. A. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 27, 205â214 (2008).
Dubash, A. D. et al. Chapter 1. Focal adhesions: new angles on an old structure. Int. Rev. Cell. Mol. Biol. 277, 1â65 (2009).
Harder, K. W., Moller, N. P., Peacock, J. W. & Jirik, F. R. Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion. J. Biol. Chem. 273, 31890â31900 (1998).
Wu, C. W., Kao, H. L., Li, A. F., Chi, C. W. & Lin, W. C. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett. 242, 95â103 (2006).
Mathew, S. et al. Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J. Biol. Chem. 283, 22709â22722 (2008).
Sahu, S. N., Nunez, S., Bai, G. & Gupta, A. Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells. Am. J. Physiol. Cell Physiol. 292, C2288âC2296 (2007).
Daouti, S. et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 68, 1162â1169 (2008).
Zeng, Q. et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 63, 2716â2722 (2003).
Guo, K. et al. Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol. Ther. 3, 945â951 (2004).
Guo, K., Tang, J. P., Tan, C. P., Wang, H. & Zeng, Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol. Ther. 7, 750â757 (2008).
Fiordalisi, J. J., Keller, P. J. & Cox, A. D. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 66, 3153â3161 (2006).
McLean, G. W., et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nature Rev. Cancer 5, 505â515 (2005).
Liang, F. et al. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase. J. Biol. Chem. 283, 10339â10346 (2008).
Fujita, Y. et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nature Cell Biol. 4, 222â231 (2002).
Sallee, J. L., Wittchen, E. S. & Burridge, K. Regulation of cell adhesion by protein-tyrosine phosphatases: II. Cell-cell adhesion. J. Biol. Chem. 281, 16189â16192 (2006).
Hellberg, C. B., Burden-Gulley, S. M., Pietz, G. E. & Brady-Kalnay, S. M. Expression of the receptor protein-tyrosine phosphatase, PTPmu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells. J. Biol. Chem. 277, 11165â11173 (2002).
Aricescu, A. R. & Jones, E. Y. Immunoglobulin superfamily cell adhesion molecules: zippers and signals. Curr. Opin. Cell Biol. 19, 543â550 (2007).
Burgoyne, A. M. et al. PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol. 11, 767â778 (2009).
Burgoyne, A. M. et al. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res. 69, 6960â6968 (2009).
Tanuma, N. et al. Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion. Oncogene 28, 752â761 (2009).
Vallat, L. et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 101, 4598â4606 (2003).
Ren, T. et al. Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer. Pathol. Oncol. Res. (2009).
Zhou, J., Wang, S., Lu, J., Li, J. & Ding, Y. Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Int. J. Cancer 124, 1879â1886 (2009).
Wang, L. et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann. Oncol. 17, 1517â1522 (2006).
Radke, I. et al. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br. J. Cancer 95, 347â354 (2006).
Wang, Y. et al. Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. Int. J. Colorectal Dis. 22, 1179â1184 (2007).
Mollevi, D. G. et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br. J. Cancer 99, 1718â1725 (2008).
Xing, X. et al. Prognostic value of PRL-3 overexpression in early stages of colonic cancer. Histopathology 54, 309â318 (2009).
Peng, L., Ning, J., Meng, L. & Shou, C. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J. Cancer Res. Clin. Oncol. 130, 521â526 (2004).
Kato, H. et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin. Cancer Res. 10, 7318â7328 (2004).
Wang, Z. et al. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int. J. Cancer 123, 1439â1447 (2008).
Wang, Z. et al. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients. Ann. Surg. Oncol. 16, 208â219 (2009).
Wang, Z. et al. Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J. Cancer Res. Clin. Oncol. 135, 1041â1046 (2009).
Miskad, U. A. et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. 450, 303â310 (2007).
Miskad, U. A., Semba, S., Kato, H. & Yokozaki, H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71, 176â184 (2004).
Li, Z. R. et al. Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. Surg. Today 37, 646â651 (2007).
Givant-Horwitz, V. et al. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 93, 517â523 (2004).
Tsujita, E. et al. Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology 69, 342â347 (2005).
Blaskovich, M. A. Drug discovery and protein tyrosine phosphatases. Curr. Med. Chem. 16, 2095â2176 (2009).
Jiang, Z. X. & Zhang, Z. Y. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 27, 263â272 (2008).
Heneberg, P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem. 16, 706â733 (2009).
Yi, T. et al. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169, 5978â5985 (2002).
Seifert, K., Escobar, P. & Croft, S. L. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J. Antimicrob. Chemother. 65, 508â511 (2010).
Liu, G. Technology evaluation: ISIS-113715, Isis. Curr. Opin. Mol. Ther. 6, 331â336 (2004).
Zhang, S. et al. Acquisition of a potent and selective TC-PTP inhibitor via a stepwise fluorophore-tagged combinatorial synthesis and screening strategy. J. Am. Chem. Soc. 131, 13072â13079 (2009).
Seco, J., Luque, F. J. & Barril, X. Binding site detection and druggability index from first principles. J. Med. Chem. 52, 2363â2371 (2009).
Combs, A. P. Recent Advances in the discovery of competitive protein tyrosine phosphatase 1b inhibitors for the treatment of diabetes, obesity, and cancer. J. Med. Chem. 53, 2333â2344 (2009).
Asante-Appiah, E. et al. Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. J. Biol. Chem. 281, 8010â8015 (2006).
Montalibet, J. et al. Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. J. Biol. Chem. 281, 5258â5266 (2006).
Bharatham, K., Bharatham, N., Kwon, Y. J. & Lee, K. W. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling. J. Comput. Aided Mol. Des. 22, 925â933 (2008).
Barr, A. J. et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352â363 (2009).
Hower, A. E., Beltran, P. J. & Bixby, J. L. Dimerization of tyrosine phosphatase PTPRO decreases its activity and ability to inactivate TrkC. J. Neurochem. 110, 1635â1647 (2009).
Tremblay, M. L. The PTP family photo album. Cell 136, 213â214 (2009).
Mattila, E. et al. Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer 10, 7 (2010).
Zbuk, K. M. & Eng, C. Cancer phenomics: RET and PTEN as illustrative models. Nature Rev. Cancer 7, 35â45 (2007).
Chan, G., Kalaitzidis, D. & Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179â192 (2008).
Mohi, M. G. & Neel, B. G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17, 23â30 (2007).
Alonso, A. et al. Protein tyrosine phosphatases in the human genome. Cell 117, 699â711 (2004). A key overview of the 107 human genes encoding PTPs, providing classification and nomenclature.
Camps, M., Nichols, A. & Arkinstall, S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14, 6â16 (2000).
Tabiti, K., Smith, D. R., Goh, H. S. & Pallen, C. J. Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas. Cancer Lett. 93, 239â248 (1995).
Berndt, A., Luo, X., Bohmer, F. D. & Kosmehl, H. Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma. Histochem. Cell Biol. 111, 399â403 (1999).
Hagerstrand, D. et al. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol. 10, 2â9 (2008).
Foehr, E. D. et al. Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 66, 2271â2278 (2006).
Ulbricht, U. et al. Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J. Neuropathol. Exp. Neurol. 62, 1265â1275 (2003).
Goldmann, T., Otto, F. & Vollmer, E. A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas. Folia Histochem. Cytobiol 38, 19â20 (2000).
Muller, S. et al. A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22, 6661â6668 (2003).
Konishi, N. et al. Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas. Br. J. Cancer 88, 1223â1228 (2003).
Yang, T., Zhang, J. S., Massa, S. M., Han, X. & Longo, F. M. Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue. Mol. Carcinog. 25, 139â149 (1999).
Levea, C. M., McGary, C. T., Symons, J. R. & Mooney, R. A. PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer. Breast Cancer Res. Treat 64, 221â228 (2000).
Vezzalini, M. et al. Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. Histopathology 50, 615â628 (2007).
Wiener, J. R. et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl Cancer Inst. 86, 372â378 (1994).
Wiener, J. R. et al. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am. J. Obstet. Gynecol. 170, 1177â1183 (1994).
Wu, C. et al. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate 66, 1125â1135 (2006).
Wu, C. W. et al. PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. Anticancer Res. 26, 1643â1649 (2006).
Warabi, M., Nemoto, T., Ohashi, K., Kitagawa, M. & Hirokawa, K. Expression of protein tyrosine phosphatases and its significance in esophageal cancer. Exp. Mol. Pathol. 68, 187â195 (2000).
Mok, S. C., Kwok, T. T., Berkowitz, R. S., Barrett, A. J. & Tsui, F. W. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecol. Oncol. 57, 299â303 (1995).
Stephens, B., Han, H., Hostetter, G., Demeure, M. J. & Von Hoff, D. D. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol. Cancer Ther. 7, 202â210 (2008).
Liu, Y. Q., Li, H. X., Lou, X. & Lei, J. Y. Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma. Arch. Pathol. Lab. Med. 132, 1307â1312 (2008).
Ming, J., Liu, N., Gu, Y., Qiu, X. & Wang, E. H. PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology 41, 118â126 (2009).
Dai, N., Lu, A. P., Shou, C. C. & Li, J. Y. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. World J. Gastroenterol. 15, 1499â1505 (2009).
Polato, F. et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin. Cancer Res. 11, 6835â6839 (2005).
Kong, L., Li, Q., Wang, L., Liu, Z. & Sun, T. The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas. Neuropathology 27, 516â521 (2007).
Fagerli, U. M. et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 111, 806â815 (2008).
Zhao, W. B., Li, Y., Liu, X., Zhang, L. Y. & Wang, X. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma. Int. J. Mol. Med. 22, 187â192 (2008).
Bang, Y. J., Kwon, J. H., Kang, S. H., Kim, J. W. & Yang, Y. C. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem. Biophys. Res. Commun. 250, 43â47 (1998).
Colombo, J. et al. Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol. Rep. 21, 649â663 (2009).
Tomioka, H., Morita, K., Hasegawa, S. & Omura, K. Gene expression analysis by cDNA microarray in oral squamous cell carcinoma. J. Oral Pathol. Med. 35, 206â211 (2006).
Vicent, S. et al. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin. Cancer Res. 10, 3639â3649 (2004).
Wang, H. Y., Cheng, Z. & Malbon, C. C. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191, 229â237 (2003).
Rojo, F. et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin. Cancer Res. 15, 3530â3539 (2009).
Liao, Q. et al. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 124, 1830â1845 (2003).
Loda, M. et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149, 1553â1564 (1996).
Denkert, C. et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer 102, 507â513 (2002).
Magi-Galluzzi, C. et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76, 37â51 (1997).
Henkens, R. et al. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 8, 147 (2008).
Levy-Nissenbaum, O. et al. Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene 22, 7649â7660 (2003).
Levy-Nissenbaum, O. et al. Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Lett. 199, 185â192 (2003).
Lee, S. W., Reimer, C. L., Fang, L., Iruela-Arispe, M. L. & Aaronson, S. A. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol. Cell Biol. 20, 1723â1732 (2000).
Yeh, C. T., Lu, S. C., Chen, T. C., Peng, C. Y. & Liaw, Y. F. Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res. 60, 4697â4700 (2000).
Ardini, E. et al. Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene 19, 4979â4987 (2000).
Nair, P., De Preter, K., Vandesompele, J., Speleman, F. & Stallings, R. L. Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. Genes Chromosomes Cancer 47, 197â202 (2008).
Cheung, A. K. et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res. 68, 8137â8145 (2008).
Liu, S. et al. Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents. Breast Cancer Res. Treat 71, 21â35 (2002).
van Niekerk, C. C. & Poels, L. G. Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors. Cancer Lett. 137, 61â73 (1999).
Nagano, H. et al. Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma. Oncogene 22, 4656â4663 (2003).
McArdle, L. et al. Protein tyrosine phosphatase genes downregulated in melanoma. J. Invest. Dermatol. 117, 1255â1260 (2001).
Zhang, Y. et al. Cytogenetical assignment and physical mapping of the human R-PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 6q22.2-q22.3. Genomics 51, 309â311 (1998).
Nakamura, M. et al. Novel tumor suppressor loci on 6q22â23 in primary central nervous system lymphomas. Cancer Res. 63, 737â741 (2003).
Motiwala, T. et al. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. J. Biol. Chem. 284, 455â464 (2009).
Ramaswamy, B. et al. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol. Endocrinol. 23, 176â187 (2009).
Mori, Y. et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 64, 2434â2438 (2004).
Lu, X. et al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood 112, 4098â4108 (2008).
Chim, C. S., Fung, T. K., Cheung, W. C., Liang, R. & Kwong, Y. L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103, 4630â4635 (2004).
Ksiaa, F., Ziadi, S., Amara, K., Korbi, S. & Trimeche, M. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin. Chim. Acta 404, 128â133 (2009).
Zhang, Q., Raghunath, P. N., Vonderheid, E., Odum, N. & Wasik, M. A. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Pathol. 157, 1137â1146 (2000).
Chim., C. S., Liang, R., Leung, M. H. & Kwong, Y. L. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J. Clin. Pathol. 60, 104â106 (2007).
Amin, H. M. et al. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J. Pathol. 212, 402â410 (2007).
Gauffin, F. et al. Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. Pediatr. Hematol. Oncol. 26, 48â56 (2009).
Cariaga-Martinez, A. E. et al. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv. Urol., 723831 (2009).
Fridberg, M. et al. Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. Pediatr. Hematol. Oncol. 25, 528â540 (2008).
Yao, H., Song, E., Chen, J. & Hamar, P. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br. J. Cancer 91, 1718â1725 (2004).
Lee, S. H. et al. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J. Pathol. 188, 207â212 (1999).
Glondu-Lassis, M. et al. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res. 70, 5116â5126 (2010).
Revillion, F. et al. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int. J. Cancer 124, 638â643 (2009).
Guimaraes, G. S. et al. Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes Chromosomes Cancer 45, 540â553 (2006).
Manzano, R. G. et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 21, 4435â4447 (2002).
Kim, S. C. et al. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93, 3893â3899 (1999).
Armes, J. E. et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23, 5697â5702 (2004).
Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S. & Horii, A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am. J. Pathol. 162, 1807â1815 (2003).
Chan, D. W. et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29, 1742â1750 (2008).
Kibel, A. S. et al. Expression mapping at 12p12â13 in advanced prostate carcinoma. Int. J. Cancer 109, 668â672 (2004).
Yu, Y. et al. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 67, 130â138 (2007).
Acknowledgements
The authors regret that, owing to space limitations, they could not mention the work of many investigators who have greatly contributed to the current knowledge of PTPs and their functions. The authors would like to thank B. P. Kennedy (Merck Frosst Center for Therapeutic Research, Canada), A. Pause (Goodman Cancer Research Centre, McGill University, Canada) and M. Meaney (Douglas Institute, McGill University, Canada and the Singapore Institute for Clinical Sciences) for discussions during the course of this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- DNA methylation
-
An addition of methyl groups to DNA, most commonly at CpG sites, to convert cytosine to 5-methylcytosine. Cytosine hypermethylation in gene promoters, leading to gene silencing, is the most frequent mechanism of tumour suppressor gene silencing in human tumours.
- Loss of heterozygosity
-
(LOH). The loss of the normal allele of a gene in which the other allele was already inactivated, leading to a complete loss of gene expression.
- Frameshift mutation
-
Caused by an insertion or deletion within a gene, which disrupts the reading frame and frequently results in severe malignancies or diseases.
- Amplification
-
A type of copy number gain in which there is a copy number of more than two; amplifications are often seen for oncogenes.
- Single nucleotide polymorphism
-
(SNP). A variation of a single nucleotide in the genomic sequence between paired chromosomes. Usually silent or does not alter gene expression or the protein, although there are numerous examples of SNPs increasing the risk of developing cancer.
- Missense mutation
-
A point mutation in which a single nucleotide is changed that changes the encoded amino acid.
- Nonsense mutation
-
Mutation that changes a codon that encodes an amino acid to a stop codon.
Rights and permissions
About this article
Cite this article
Julien, S., Dubé, N., Hardy, S. et al. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11, 35â49 (2011). https://doi.org/10.1038/nrc2980
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2980
This article is cited by
-
Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma
BMC Cancer (2024)
-
Lactoferrin suppresses the progression of colon cancer under hyperglycemia by targeting WTAP/m6A/NT5DC3/HKDC1 axis
Journal of Translational Medicine (2023)
-
Role of protein tyrosine phosphatase receptor type M in epithelial ovarian cancer progression
Journal of Ovarian Research (2023)
-
The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells
Scientific Reports (2020)
-
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer
Oncogene (2020)